Journal of Biomedicine and Practice – Biomeditsina va amaliyot jurnali Том 9 № 3 (2024)
PHARMACOLOGICAL AND CLINICAL ASPECTS OF PHOSPHODIESTERASE TYPE 5 INHIBITORS IN THE TREATMENT OF ERECTILE DYSFUNCTION
GAFAROV Rushen Refatovich
Аннотация
Erectile dysfunction (ED) is an important health problem in men associated with reduced quality of life. Implementation of phosphodiesterase type 5 inhibitors (PDE-5 Is) has revolutionized the management of patients with ED and PDE-5Is are currently considered first-line therapy of ED. This paper describes characteristics of the pharmacokinetics, pharmacodynamics and possible clinical side effects of medications from the PDE-5 Is group. PDE-5Is discussed in the article include sildenafil, tadalafil, vardenafil, udenafil, avanafil, lodenafil, mirodenafil, youkenafil, SLx-2101 and simmerafil.
ингибиторы фосфодиэстеразы 5 типа, эректильная дисфункция, фармакокинетика, фармакодинамика, побочные эффектыphosphodiesterase type 5 inhibitors, erectile dysfunction, pharmacokinetics, pharmacodynamics, side effectsfosfodiesteraza 5-turi ingibitorlari, erektil disfunksiya, farmakokinetika, farmakodinamika, nojo'ya ta'sirlar
Источник метаданных: OAI-PMH архив журнала · Sindex не хранит полный текст, а даёт ссылку на источник.